Altimmune Valuation
| ALT Stock | USD 4.08 0.03 0.74% |
At this time, the firm appears to be undervalued. Altimmune shows a prevailing Real Value of $8.19 per share. The current price of the firm is $4.08. Our model approximates the value of Altimmune from analyzing the firm fundamentals such as Return On Equity of -0.57, current valuation of 190.79 M, and Shares Owned By Insiders of 0.76 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Altimmune's valuation include:
Price Book 2.3848 | Enterprise Value | Enterprise Value Ebitda (4.20) | Price Sales 16.5 K | Enterprise Value Revenue 9.5 K |
Undervalued
Today
Please note that Altimmune's price fluctuation is unstable at this time. Calculation of the real value of Altimmune is based on 3 months time horizon. Increasing Altimmune's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Altimmune's intrinsic value may or may not be the same as its current market price of 4.08, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.08 | Real 8.19 | Target 20.56 | Hype 4.04 | Naive 4.81 |
The intrinsic value of Altimmune's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Altimmune's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Altimmune helps investors to forecast how Altimmune stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Altimmune more accurately as focusing exclusively on Altimmune's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Altimmune's intrinsic value based on its ongoing forecasts of Altimmune's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Altimmune's closest peers.
Altimmune Cash |
|
Altimmune Valuation Trend
Altimmune's real value is important for investors to make better decisions and a more accurate overall view of Altimmune's financial worth over time. Using both Altimmune's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Altimmune Total Value Analysis
Altimmune is presently expected to have company total value of 190.79 M with market capitalization of 330.92 M, debt of 1.68 M, and cash on hands of 184.76 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Altimmune fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
190.79 M | 330.92 M | 1.68 M | 184.76 M |
Altimmune Investor Information
About 48.0% of the company shares are held by institutions such as insurance companies. The book value of Altimmune was presently reported as 1.83. The company recorded a loss per share of 1.26. Altimmune last dividend was issued on the 20th of January 2017. The entity had 1:30 split on the 14th of September 2018. Based on the measurements of operating efficiency obtained from Altimmune's historical financial statements, Altimmune may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Altimmune Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Altimmune has an asset utilization ratio of 0.0144 percent. This implies that the Company is making $1.44E-4 for each dollar of assets. An increasing asset utilization means that Altimmune is more efficient with each dollar of assets it utilizes for everyday operations.Altimmune Ownership Allocation
Altimmune holds a total of 81.11 Million outstanding shares. 30% of Altimmune outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Altimmune Profitability Analysis
The company reported the last year's revenue of 20 K. Reported Net Loss for the year was (95.06 M) with loss before taxes, overhead, and interest of (76.55 M).About Altimmune Valuation
The stock valuation mechanism determines Altimmune's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Altimmune based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Altimmune. We calculate exposure to Altimmune's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Altimmune's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 20 K | 19 K | |
| Pretax Profit Margin | -4.8 K | -5 K | |
| Operating Profit Margin | -5.2 K | -4.9 K | |
| Net Loss | -4.8 K | -4.5 K | |
| Gross Profit Margin | (0.12) | (0.11) |
Altimmune Growth Indicators
Investing in growth stocks can be very risky. If the company such as Altimmune does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 71 M |
Altimmune Current Valuation Indicators
Altimmune's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Altimmune's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Altimmune, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Altimmune's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Altimmune's worth.Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.